Why Alzheimer’s May Be Biopharma’s Most Challenging Target

Don Seifert opines that treatment of Alzheimer’s is one of biopharma’s most difficult goals not only because the number of deaths from Alzheimer’s increases as baby boomers age, but also because drug trials have been focused on patients already exhibiting symptoms rather than on prevention in the symptom-free decades in which beta amyloids build up in the brain.
Boston Business Journal